Pharmaceutical and Medical Device Manufacturing
By vaayaa Editorial Team · Subject panel: Robert Anderson (MBA, Operations Management), Budi Hartono (B.Tech, Electrical Engineering)
Drug and device production turns active ingredients, components and sterile processes into medicines and medical equipment under strict quality rules. A learner can build the core of this work through self-paced study of GMP, quality assurance, validation and regulation [1][2].
Key takeaways
- Good Manufacturing Practices cover premises, equipment, raw materials and staff, so process control and records matter as much as the finished product [2].
- India's pharmaceutical sector is moving from volume toward complex generics, biosimilars and innovation, while device exports have grown quickly [3][4].
- Device makers often struggle most with complaint handling, corrective and preventive action, and process validation [5].
- Entry routes and job content are set out in national curricula, which list production support, packaging and quality modules [1][6].
- A practical learning route starts with GMP and quality basics, then moves to validation, risk and regulation [6][2][7].
Drug and device production is the work of turning ingredients, components and sterile processes into products that patients can use safely. It covers medicines such as tablets and injectables, and devices such as stents, scanners and ventilators. India offers a clear view of the scale: the Economic Survey says the pharmaceutical industry is shifting from a volume-driven approach to a value-driven one, with more emphasis on complex generics, biosimilars and innovation [3].
The field rewards precision in ways that many other industries do not. A batch record, a calibration log or a cleaning report can decide whether a product reaches the market. Regulators look at the process and the environment as closely as the finished item, which is why GMP guidance covers raw materials, premises, equipment and the training and hygiene of staff [2].
This discourse explains what the work involves, which skills matter, how facilities operate, where jobs sit and how a learner can build competence through self-paced, text-based study. It draws on government reports, industry data and regulator case studies, and it labels facts, estimates and opinions.
Where drug and device production sits in the economy
India's pharmaceutical industry is the world's third-largest by volume and meets approximately 20 per cent of global generics demand, according to the Economic Survey as reported by the government's Press Information Bureau [3]. Another analysis says the country supplies generics to 191 markets, more than half of them highly regulated jurisdictions such as the US and Europe [4]. Those markets set the standard for paperwork and inspection readiness.
Devices form a connected but separate branch. The same survey notes that domestic makers now produce MRI and CT scanners, linear accelerators, cardiac stents and ventilators [3]. Medical device exports rose from USD 2.5 billion to USD 4.1 billion in the survey's own comparison, a sign of movement toward high-tech manufacturing [3][4].
Globally, an annual market report by Alira Health puts the medtech contract development and manufacturing market at $96.5 billion, reflecting 8.4% year-over-year growth [8]. The same report describes pharma and medtech convergence, which means drug and device work is increasingly handled under integrated arrangements [8][9].
Fact The Economic Survey reports that medical device exports grew from USD 2.5 billion to USD 4.1 billion [3].
Core knowledge areas: GMP, quality systems and validation
Good Manufacturing Practices sit at the center of the field. The guidance describes them as practices that ensure products are consistently produced and controlled to quality standards, with the focus on processes and environments rather than only the final test [2]. Learners who understand GMP can read almost any site procedure with a clear purpose in mind.
Quality assurance and quality control
Quality assurance and quality control are different jobs. A national model curriculum for production and packaging work lists the difference as a core outcome, together with regulatory compliance, ISO 9001 and continuous improvement methods such as Lean Six Sigma [6]. The same curriculum includes environmental sustainability, packaging fundamentals and cleaning in GMP-controlled areas [1][6].
Validation and root cause work
Validation is the documented proof that a process, piece of equipment or test method does what it is meant to do. A validation engineer role in the sector asks for a site validation program covering products, processes, equipment, software and test methods, with reference to ISO 13485 and ISO 14971 [7]. The same role requires root cause analysis and corrective actions [7].
Fact Manufacturers must keep detailed records that trace every stage of production, so issues can be identified after a product reaches the market [2].
Source: vaayaa analysis of cited data
View chart data
| Approved outlay | 6,940 Rs crore |
| Committed investment | 4,330 Rs crore |
| Recorded investment | 5,211 Rs crore |
| Beneficiary sales | 3,792 Rs crore |
| Beneficiary exports | 560.16 Rs crore |
Tools, methods and production technologies
Modern plants depend on digital networking between machines, molds, automation and control systems. In one demonstration project for injector pen caps, the partners described networked machine, mold and automation functions as a way to improve part quality and reduce energy use [10]. Those benefits are the project's own claims, so readers should treat them as opinion rather than measured results.
Assembly and sterile filling are increasingly integrated under one roof. Thermo Fisher and SHL Medical announced a partnership to integrate autoinjector assembly with sterile fill-finish at a New Jersey site [11]. Patent literature describes aseptic chambers where device closures and bodies are formed, sealed and transferred in sterile conditions [12].
Risk and quality methods are the everyday tools. Failure mode analysis and hazard analysis methods such as FMEA and HACCP appear in risk guidance [13]. Inspection data also points to the systems that matter most: FDA inspection observations show that procedures, complaint handling and corrective and preventive action are frequent weak points [5].
- Standard operating procedures and batch records
- Calibration, cleaning and environmental monitoring logs
- Root cause analysis and corrective and preventive action (CAPA) files
- Validation protocols and test method validation
- Electronic quality management systems and digital data records
| Aspect | Medicines manufacturing | Device manufacturing | Contract manufacturing | Basis |
|---|---|---|---|---|
| Main output | Generic and biosimilar drugs for many markets | MRI and CT scanners, stents, ventilators | Integrated drug and device services for clients | Fact |
| Scale signal | Exports to 191 markets | Exports of USD 4.1 billion | Market of $96.5 billion | Fact |
| Core rulebook | Drugs Rules and licensing under the Drugs and Cosmetics Act | Good Manufacturing Practices with validation and traceable records | Pharma and medtech integration across development and manufacturing | Fact |
| Main weakness reported | Investigation quality and documentation gaps | Complaint handling, CAPA, process validation | Capability expansion and consolidation pressure | Opinion |
| Growth figure | Pharma PLI outlay of Rs 15,000 crore | Device exports up from USD 2.5 billion to USD 4.1 billion | Projected 8.3% CAGR | Fact |
Real-world applications from plant floors to market access
Facility scale-up is a major application. Eli Lilly's Concord campus in North Carolina is described as a fully paperless, automated parenteral manufacturing site, built on greenfield land and approved by the US Food and Drug Administration in 30 months [14]. The project overlapped interior fit-out with building completion and reused validated design platforms, which cut engineering rework [14].
Reshoring is another application. Companies in pharmaceutical, biotechnology and device work are bringing operations closer to home to gain supply visibility and quality oversight [15]. Logistics teams must also keep temperature-sensitive, high-value products moving across borders while meeting customs and regulatory rules [16].
The same logic appears in outsourcing. Thermo Fisher's Ridgefield, New Jersey site was acquired from Sanofi and is being developed into a hub for sterile fill-finish, autoinjector final assembly and packaging [11].
Source: vaayaa analysis of cited data
View chart data
| Micro-molding investment | 37% |
| Sterile packaging investment | 43% |
| Precision machining investment | 46% |
| Drug delivery share of transactions | 22% |
Roles, entry routes and employment signals
The national model curriculum for manufacturing and packaging assistants in pharmaceuticals, biologics and medical devices is set at NSQF Level 3. Its entry route accepts a 10th pass or an NSQF Level 2 certificate, with a minimum of three years of experience in the life sciences sector [1]. The program includes 60 hours of employability skills and an apprenticeship module [1].
Quality roles usually ask for more. A quality assurance specialist module covers quality planning, stakeholder roles and quality frameworks such as CMMI [6]. A validation engineer posting in the sector asks for a bachelor's degree in science or engineering, together with audit and corrective action skills [7].
Employment follows investment. The government's Production Linked Incentive scheme for bulk drugs reports that its beneficiaries generated employment for around 5,127 people [19]. A survey of life sciences professionals by Grand Avenue Software lists skilled labor shortages as an escalating operational risk [20].
- Production and packaging assistant: GMP practice, documentation, cleaning, EHS rules
- Quality assurance specialist: audits, quality systems, continuous improvement
- Validation engineer: validation programs, root cause analysis, compliance
- Regulatory affairs and compliance roles: submissions, inspection readiness
Regulation, risk and the cost of getting it wrong
Regulation is changing. A draft Drugs, Medical Devices and Cosmetics Bill proposed by the Ministry of Health and Family Welfare would create a dedicated framework for medical devices, including risk-based regulation and stronger oversight [21]. Industry associations and patient groups have opposed the draft, arguing that devices are engineering products and should not be regulated as drugs [22].
Opinion Industry groups argue that medical devices need their own regulatory foundation. This is their position, not a finding from an independent review [22].
Existing law already sets firm limits. Under the Drugs and Cosmetics Act, a person may not manufacture, sell or distribute drugs or cosmetics without a license, and packaging and labelling must follow the rules [23]. Trade risk is also visible: the United States has threatened 100% tariffs on imported pharmaceuticals, and supply disruptions have forced several plants to slow production [24].
Risk thinking is changing too. One expert argues that event-based methods such as FMEA focus on bad outcomes rather than the processes that produce them, and suggests analyzing risk mechanisms directly [13]. Enterprise risk management frames supply chains, tariffs and cyber risk as connected threats to production [25].
Building competence step by step through self-paced study
A learner does not need a factory to start. Self-paced, text-based study can build a working vocabulary, a sense of quality systems and an understanding of how regulators judge evidence. The most useful order is to begin with GMP, move to quality and validation, then add regulation and risk, and finish with a written project.
Each stage should end with a written check. Summarize a GMP guidance section, draft a short corrective action report, or compare two regulatory approaches. These exercises show whether the concepts have been understood, which is more useful than a certificate alone.
Assumption The study route assumes the reader has basic reading comfort with technical documents. Learners without a science background may need extra time on the validation and regulation stages.
Original analysis
vaayaa analysis: device export growth and PLI sales against outlay
- Take the device export figures reported in the Economic Survey: USD 2.5 billion earlier and USD 4.1 billion later [3].
- Subtract the earlier figure from the later one: 4.1 minus 2.5 equals 1.6.
- Divide the change by the earlier figure: 1.6 divided by 2.5 equals 0.64, or 64 percent growth.
- Take beneficiary sales of Rs 3,792.49 crore and the approved outlay of Rs 6,940 crore [19].
- Divide sales by outlay: 3,792.49 divided by 6,940 equals 0.546, or 54.6 percent.
- Compare recorded investment of Rs 5,210.74 crore with committed investment of Rs 4,330 crore: the difference is 880.74, and 880.74 divided by 4,330 equals 0.203, or 20.3 percent above commitment.
On the reported totals, device exports rose about 64 percent, and beneficiary sales equal about 55 percent of the approved outlay, while recorded investment exceeded commitments by about 20 percent. These are arithmetic results on published totals, not a survey or experiment, and sales are not a direct measure of profit.
A five-stage self-paced route into drug and device manufacturing
- 1
Learn GMP basics
Read a GMP guide and summarize how it covers premises, equipment, materials and staff training [2].
- 2
Study quality systems
Compare quality assurance with quality control, then review ISO 9001, CMMI and Lean Six Sigma [6].
- 3
Add validation and risk
Study validation programs, root cause analysis and risk standards such as ISO 14971 [7][13].
- 4
Cover regulation
Review the licensing rules in the Drugs and Cosmetics Act and the proposed device framework [21][23].
- 5
Write a project
Draft a written batch review or corrective action report that applies the earlier stages to a sample case.
Worked example
Measuring how far recorded investment exceeded commitments
- Identify the committed investment: Rs 4,330 crore [19].
- Identify the recorded investment: Rs 5,210.74 crore [19].
- Subtract commitment from recorded investment: 5,210.74 minus 4,330 equals 880.74.
- Divide the difference by the commitment: 880.74 divided by 4,330 equals 0.2034.
- Convert to a percentage: 0.2034 times 100 equals 20.3 percent.
Recorded investment in the scheme was about 20.3 percent above the committed figure, which is a useful way for a learner to read investment reports in this sector.
Practical checklist before starting a study route
- Read a GMP guide and list the five areas it covers [2].
- Define quality assurance and quality control in your own words [6].
- Summarize one regulatory proposal and note the arguments on each side [21][22].
- Identify two risk tools and explain what each one measures [13].
- Write one short corrective action report for a made-up deviation.
Frequently asked questions
What does the field involve day to day?
Day to day work includes following written procedures, filling batch and cleaning records, and checking that equipment and processes stay within set limits. Staff also support packaging, handle deviations and prepare documents for audits [1][2]. Clear documentation is central, because regulators judge whether activities were performed and controlled as required [5].
Is this field only about medicines?
No. The sector includes drugs, biologics and medical devices. Device work covers scanners, stents and ventilators, and many plants handle both drugs and devices [3][8]. Regulators apply separate rules to each, and industry groups argue that devices should not be treated as medicines [22].
What qualification does an entry role usually need?
The national curriculum for production assistants accepts a 10th pass or an NSQF Level 2 certificate, with at least three years of experience in life sciences [1]. Quality and validation roles often ask for a bachelor's degree in science or engineering [7].
Why does quality matter so much here?
Products are used by patients, so defects can cause serious harm. Good Manufacturing Practices aim to ensure products are consistently made to quality standards [2]. Inspection findings show that procedures and corrective actions are frequent weak points for manufacturers [5].
How do trade and supply issues affect the work?
Tariffs raise costs for imported ingredients and devices, which can be passed on to patients [16]. Supply disruptions have forced some plants to partially suspend operations [24]. These pressures explain the move toward reshoring and better supply visibility [15].
Can a learner build competence without a factory?
Yes, a learner can build a strong base through self-paced reading of GMP, quality and validation material, followed by written exercises. Stages such as writing a corrective action report show whether concepts are understood [2][7]. Practical experience at a site still adds value later.
Conclusion
Drug and device production combines regulated processes, quality systems and supply chain control. The sector is growing and shifting toward higher value products, from complex generics to imaging and life-support devices [3][4]. Its rules are tight, and regulators judge records and procedures as closely as the product.
A learner who starts with GMP, moves through quality and validation, and then studies regulation and risk will have a sound base for entry roles. The next step is to test that understanding through written projects and to watch how the proposed device framework and trade pressures develop [21][24].
Learning sources
References
- nqr.gov.in. Model Curriculum.
- qualio.com. Good Manufacturing Practices (GMP) explained.
- pib.gov.in. Economic Survey -26 Highlights India’s Shift Toward High-Value Pharma and Innovation.
- forbesindia.com. Economic Survey: Pharma scale up collides with obesity, NCD boom - Advertisement.
- pharmout.net. How Inspection Findings Trends Can Guide Manufacturer Actions.
- nqr.gov.in. Terminal Outcomes.
- ichgcp.net. Validation Engineer - Validation Engineer.
- markets.businessinsider.com. Global Medtech CDMO Market Grows to $96.5B in as Pharma-Medtech Convergence Emerges as a Defining Accelerator - Global Medtech CDMO Market Grows to $96.5B in as Pharma-Medtech Convergence Emerges as a Defining Accelerator.
- di.se. Pressmeddelande - Hoppa till innehållet.
- reinraum.de. Project with Sanofi: Groundbreaking digital production cell for medical technology.
- manufacturingchemist.com. Thermo Fisher and SHL Medical collaborate to integrate autoinjector assembly with sterile fill-finish at Ridgefield site.
- patentimages.storage.googleapis.com. In one embodiment of the present invention, the apparatus further comprises at least one assembly device including the at least ....
- outsourcedpharma.com. Why Pharmaceutical And Medical Device Risks Must Be Analyzed By Their Risk Mechanisms - Get more pharma outsourcing insight with our FREE newsletter.
- ispe.org. ISPE Facility of the Year Awards (FOYA) Category Winner for Operations - Project Execution.
- emmainternational.com. Reshoring and Manufacturing Scale-Up: Navigating Growth While Maintaining Compliance - EMMA International.
- pharmafocuseurope.com. Navigating the Complexities of Life Sciences Logistics.
- gov.uk. MHRA assists development of UK manufacturing site for innovative drug-device product - MHRA assists development of UK manufacturing site for innovative drug-device product.
- gov.uk. Innovation: early dialogue with MHRA shapes development of UK manufacturing site - Innovation: early dialogue with MHRA shapes development of UK manufacturing site.
- ibef.org. Production Linked Incentive Schemes have Strengthened India’s Pharmaceutical, Bulk Drugs and Medical Devices Manufacturing Ecosystem | IBEF - Production Linked Incentive Schemes have Strengthened India’s Pharmaceutical, Bulk Drugs and Medical Devices Manufacturing Ecosy....
- medicaldesignandoutsourcing.com. Grand Avenue report examines life sciences readiness.
- jsalaw.com. JSA Newsletter | Healthcare | August Edition - JSA.
- health.economictimes.indiatimes.com. Medical devices are not pharma products, companies say while opposing Draft Bill - Medical devices are not pharma products, companies say while opposing Draft Bill.
- chambers.com. Additionally, the Drugs Rules provide an inclusive definition of “manufacturer”, which includes “a manufacturer of drugs, who ma....
- worldview.ranenetwork.com. The Growth Outlook for India's Pharmaceutical Sector Remains Strong, Despite Global Uncertainties.
- bdo.com. Enterprise Risk Management - Life Sciences Industry Spotlight.